Imagine if Starpharma had used this same VC model back in 2012 to create a start-up company with AstraZeneca to drive the development of AZD0466.
Guess what the value of Starpharma’s 22.5% of the company would be today after 12 years. A big fat ZERO.
And they would never have received an initial licence fee and they wouldn’t have received a milestone payment when AZD0466 progressed into Phase One from pre-clinical.
What a great business model that would have been … for AstraZeneca.
Imagine if Starpharma had used this same VC model back in 2012...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |